Wouldn’t that be quite the positive turn of events for Elite!
I have good reason to believe the results will show at least a modest benefit for isradipine. This is a high-quality, prospective study over *3 years.* Very rare to see this long of a study, and this one is designed to pick up even a small benefit of 25% reduction in disability over 3 years. Also, there were several checkpoints where interim data was analyzed for futility. If there was no benefit at all, the study would have been halted. So we know that the drug is well-tolerated because the participant retention rate is very high, and we know the drug is not futile because the study was not halted. And don't forget free. I like free.
Market Data 
Markets 
AI
